vs

Side-by-side financial comparison of Service Properties Trust (SVC) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Service Properties Trust is the larger business by last-quarter revenue ($296.5M vs $151.7M, roughly 2.0× Tarsus Pharmaceuticals, Inc.). Service Properties Trust runs the higher net margin — -0.3% vs -5.5%, a 5.3% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -17.0%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-95.2M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -6.1%).

Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

SVC vs TARS — Head-to-Head

Bigger by revenue
SVC
SVC
2.0× larger
SVC
$296.5M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+145.4% gap
TARS
128.4%
-17.0%
SVC
Higher net margin
SVC
SVC
5.3% more per $
SVC
-0.3%
-5.5%
TARS
More free cash flow
TARS
TARS
$108.1M more FCF
TARS
$13.0M
$-95.2M
SVC
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-6.1%
SVC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SVC
SVC
TARS
TARS
Revenue
$296.5M
$151.7M
Net Profit
$-782.0K
$-8.4M
Gross Margin
Operating Margin
-3.9%
-5.3%
Net Margin
-0.3%
-5.5%
Revenue YoY
-17.0%
128.4%
Net Profit YoY
99.0%
63.8%
EPS (diluted)
$-0.01
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SVC
SVC
TARS
TARS
Q4 25
$296.5M
$151.7M
Q3 25
$377.6M
$118.7M
Q2 25
$404.4M
$102.7M
Q1 25
$335.0M
$78.3M
Q4 24
$357.0M
$66.4M
Q3 24
$390.9M
$48.1M
Q2 24
$412.5M
$40.8M
Q1 24
$336.2M
$27.6M
Net Profit
SVC
SVC
TARS
TARS
Q4 25
$-782.0K
$-8.4M
Q3 25
$-46.9M
$-12.6M
Q2 25
$-38.2M
$-20.3M
Q1 25
$-116.4M
$-25.1M
Q4 24
$-76.4M
$-23.1M
Q3 24
$-46.9M
$-23.4M
Q2 24
$-73.8M
$-33.3M
Q1 24
$-78.4M
$-35.7M
Operating Margin
SVC
SVC
TARS
TARS
Q4 25
-3.9%
-5.3%
Q3 25
-12.8%
-12.2%
Q2 25
-9.2%
-21.6%
Q1 25
-33.3%
-33.5%
Q4 24
-19.4%
-36.8%
Q3 24
-12.8%
-52.3%
Q2 24
-17.1%
-81.6%
Q1 24
-21.4%
-136.5%
Net Margin
SVC
SVC
TARS
TARS
Q4 25
-0.3%
-5.5%
Q3 25
-12.4%
-10.6%
Q2 25
-9.4%
-19.8%
Q1 25
-34.8%
-32.1%
Q4 24
-21.4%
-34.8%
Q3 24
-12.0%
-48.7%
Q2 24
-17.9%
-81.6%
Q1 24
-23.3%
-129.4%
EPS (diluted)
SVC
SVC
TARS
TARS
Q4 25
$-0.01
$-0.17
Q3 25
$-0.28
$-0.30
Q2 25
$-0.23
$-0.48
Q1 25
$-0.70
$-0.64
Q4 24
$-0.46
$-0.57
Q3 24
$-0.28
$-0.61
Q2 24
$-0.45
$-0.88
Q1 24
$-0.48
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SVC
SVC
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$346.8M
$417.3M
Total DebtLower is stronger
$5.5B
$72.4M
Stockholders' EquityBook value
$646.1M
$343.4M
Total Assets
$6.5B
$562.2M
Debt / EquityLower = less leverage
8.52×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SVC
SVC
TARS
TARS
Q4 25
$346.8M
$417.3M
Q3 25
$417.4M
$401.8M
Q2 25
$63.2M
$381.1M
Q1 25
$80.1M
$407.9M
Q4 24
$143.5M
$291.4M
Q3 24
$48.6M
$317.0M
Q2 24
$14.6M
$323.6M
Q1 24
$71.3M
$298.5M
Total Debt
SVC
SVC
TARS
TARS
Q4 25
$5.5B
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$5.8B
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
SVC
SVC
TARS
TARS
Q4 25
$646.1M
$343.4M
Q3 25
$647.9M
$335.1M
Q2 25
$695.9M
$332.6M
Q1 25
$734.6M
$342.5M
Q4 24
$851.9M
$224.5M
Q3 24
$929.0M
$237.5M
Q2 24
$1.0B
$252.2M
Q1 24
$1.1B
$275.2M
Total Assets
SVC
SVC
TARS
TARS
Q4 25
$6.5B
$562.2M
Q3 25
$7.0B
$534.6M
Q2 25
$6.9B
$495.0M
Q1 25
$7.0B
$500.8M
Q4 24
$7.1B
$377.0M
Q3 24
$7.1B
$376.3M
Q2 24
$7.1B
$376.8M
Q1 24
$7.2B
$349.3M
Debt / Equity
SVC
SVC
TARS
TARS
Q4 25
8.52×
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
6.85×
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SVC
SVC
TARS
TARS
Operating Cash FlowLast quarter
$-18.5M
$19.3M
Free Cash FlowOCF − Capex
$-95.2M
$13.0M
FCF MarginFCF / Revenue
-32.1%
8.6%
Capex IntensityCapex / Revenue
25.9%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-107.0M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SVC
SVC
TARS
TARS
Q4 25
$-18.5M
$19.3M
Q3 25
$98.1M
$18.3M
Q2 25
$-7.0K
$-29.4M
Q1 25
$38.2M
$-20.7M
Q4 24
$-9.7M
$-22.2M
Q3 24
$106.2M
$-8.7M
Q2 24
$43.8M
$-14.4M
Q1 24
$-926.0K
$-37.8M
Free Cash Flow
SVC
SVC
TARS
TARS
Q4 25
$-95.2M
$13.0M
Q3 25
$57.9M
$16.3M
Q2 25
$-46.6M
$-30.4M
Q1 25
$-23.2M
$-21.2M
Q4 24
$-88.9M
$-22.3M
Q3 24
$24.1M
$-8.9M
Q2 24
$-22.3M
$-15.4M
Q1 24
$-77.2M
$-38.0M
FCF Margin
SVC
SVC
TARS
TARS
Q4 25
-32.1%
8.6%
Q3 25
15.3%
13.8%
Q2 25
-11.5%
-29.6%
Q1 25
-6.9%
-27.1%
Q4 24
-24.9%
-33.5%
Q3 24
6.2%
-18.6%
Q2 24
-5.4%
-37.8%
Q1 24
-23.0%
-137.5%
Capex Intensity
SVC
SVC
TARS
TARS
Q4 25
25.9%
4.2%
Q3 25
10.6%
1.6%
Q2 25
11.5%
1.0%
Q1 25
18.3%
0.8%
Q4 24
22.2%
0.1%
Q3 24
21.0%
0.6%
Q2 24
16.0%
2.5%
Q1 24
22.7%
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons